Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New Corporate Presentation is up

<< Previous

Bullboard Posts

Next >>

Comment by Spartrapon Mar 05, 2021 3:50pm

80 Views

Post# 32730852

RE:RE:RE:RE:RE:RE:New Corporate Presentation is up

Most certainly the latter. Those studies need around 20 to 30 patients to reach power I think.

qwerty22 wrote:

Is this an efficacy study or are they just showing bio-equivalence type studies, showing IM has same pharmaco profile as IV?

Spartrap wrote:

Well I assumed "conducted" (footnotes on page 6 and 7) meant TH is footing the bill.

Maybe not, or maybe costs are shared..but then wouldn't the corporate document make that unambiguous?

SPCEO1 wrote: Where did you see that TH is footing the bill for the IM Trogarzo trial?

Spartrap wrote:
Was it known that the Trogarzo's IM study is to be conducted by Thera?

Wonder how much this is going to cost, on top of the two other european trog studies.. (ouch)

scarlet1967 wrote:

For R&D looking through it quickly they added the fast track for PDC and study may proceed for both protocols.

The commercializing strategies seems to have few new additions, note they are saying the Trogarzo market opportunity could be as much as US!

“New Go-to-Market Strategy Underpinned by Sales Force Reorganization and Targeted Patient / Prescriber Education.

Leverage existing localized KOL relationships to capture HIV market opportunities, which could scale to parity with the U.S.

Targeted and frequent educational initiatives to key KOLs, patients and the HIV community.”

SPCEO1 wrote: https://www.theratech.com/wp-content/uploads/2021/03/Corporate-Presentation_Theratehnologies_March-2021.pdf